Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.

The pharmacokinetics and potential drug-drug interactions between cetuximab and cisplatin or carboplatin from two studies (JXBA and JXBB) were evaluated. These studies were multicenter, open-label phase II trials designed to evaluate the drug-drug interactions between cetuximab (400 mg m initial dose) and cisplatin (JXBA; 100 mg m) or carboplatin (JXBB; area under the curve [AUC] = 5 mg × min mL) with or without 5-fluorouracil (5FU) in patients with advanced solid tumors. Concentrations of cetuximab, cisplatin and carboplatin were determined using analytical methods.

Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.

Purpose: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure-response relationship for progression-free survival (PFS), overall survival (OS), and safety.

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.

Background And Objectives: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved a highly significant improvement in overall survival versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma (STS). In this study, we characterize the pharmacokinetics (PKs) of olaratumab in a cancer patient population.

A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.

Introduction: Enzastaurin is an oral serine/threonine kinase inhibitor, which suppress signaling through protein kinase C-beta and the phosphatidylinositol 3-kinase/AKT pathway. Preclinical studies suggested synergic antitumor activity of enzastaurin and pemetrexed. We conducted this phase I study to evaluate the safety, pharmacokinetics, and clinical activity of this combination in patients with previously treated advanced non-small cell lung cancer.

The relationship among shame, guilt, and self-efficacy.

The perception of the self has been one of the fundamental constructs in psychotherapy, with attention devoted to shame, guilt, and, more recently, one's perception of ability to influence a situation-that is, self-efficacy; however, the relationship between these constructs merits scholarly attention. In the present study, researchers analyze the survey responses of 194 college students to determine relationships between shame and guilt as measured by the Test of Self-Conscious Affect (TOSCA 3, Tangney & Dearing, 2002), and self-efficacy as measured by the general and social self-efficacy scales (by Sherer, Maddux, Mercandante, Prentice-Dunn, Jacobs, & Rogers, 1982). Results support a hypothesis that higher shame scores were related to reduced self-efficacy; however, scores did not reveal a significant correlation between guilt and self-efficacy.